Fertility is collapsing across very different cultures for reasons that are not primarily economic. The UN records population already past its peak in 63 countries, and Africa, the one counterpoint, is following the same curve wherever cities reach.
When a conservative European pharma giant writes a $1.3 billion cheque for an RNAi company, it is worth pausing to understand what that actually means.
Hospitals have become the second most attacked sector after finance, the opioid crisis is a failure of pain management rather than a drug problem, and Africa faces fewer than three doctors per 10,000 people. Health systems are straining before the demographic weight has fully arrived.
Global life expectancy has reached 73.8 years while healthy life expectancy stands at 63.1. That 10.7-year gap, not longevity itself, is what ageing science is actually chasing — and 2026 research has begun to give the effort a molecular foundation.
Reopening a blocked vessel is not the same as saving the brain, and leaving hospital is not the same as recovering. A Japanese cohort of 18,719 patients shows how sharply risk rises after a first recurrence — and why VOSTOK ONE is working on neuroprotection.
Denis Milov has lived with multiple sclerosis for sixteen years. His MRI has been stable since 2020, his EDSS score is 4.0, and he bench-presses 100 kilograms. The biology behind that recovery points at IGF-1 — and at the question VOSTOK ONE's MS programme is built to answer.
